All Oncology News

Here is your guide to the important regulatory decisions made by the FDA in June 2024.

Dostarlimab plus chemotherapy demonstrated a meaningful overall survival improvement in primary endometrial cancer, regardless of mismatch repair status.

The FDA has granted fast track designation to the radiopharmaceutical 225Ac-FL-020 for patients with metastatic castration-resistant prostate cancer.

The FDA has granted fast track designation to Radspherin for the treatment of patients with peritoneal metastases from ovarian cancer.

Estelamari Rodriguez, MD, MPH, is breaking down barriers to care by creating Spanish-language content about lung cancer for patients and caregivers.

Sumanta Kumar Pal, MD, FASCO, highlights key renal cell carcinoma research presented at the 2024 ASCO Annual Meeting, including early data with DFF332.

Anjana Pillai, MD, details a patient case study and key takeaways from a presentation she gave at an OncLive® State of the Science Summit™ on locoregional therapies for HCC.

The American Society for Radiation Oncology has released a guideline to characterize the place of radiation therapy in HPV-associated oropharyngeal squamous cell carcinoma.

Patients with resectable gastric cancers achieved superior OS and pCR rates with perioperative pembrolizumab plus chemotherapy vs chemotherapy alone.

Tislelizumab plus chemotherapy improved OS in patients with unresectable esophageal squamous cell carcinoma and a CPS or TAP score of at least 1 vs 1%.

IBI343 was well tolerated and demonstrated signs of efficacy in patients with CLDN18.2-positive advanced gastric/GEJ adenocarcinoma.

Mitazalimab plus mFOLFIRINOX yielded early efficacy signals and a manageable safety profile for the frontline treatment of patients with mPDAC.

Cilta-cel improved overall survival vs standard regimens in relapsed/lenalidomide-refractory multiple myeloma after 1 prior line of therapy.

The FDA has received a biologics license application resubmission for cosibelimab in locally advanced or metastatic cutaneous squamous cell carcinoma.

OncLive honors 15 oncology leaders with the 2024 Giants of Cancer Care awards for their innovations in improving patient outcomes.

Fox Chase Cancer Center celebrated a gift of $10.8 million from the Estate of Concetta “Chet” Greenberg, an ardent champion of cancer research during her life.

Vivek Subbiah, MD, details the rationale for combining sapanisertib with ziv-aflibercept or metformin and next steps for mTOR inhibitors in solid tumors.

The EMA recommends durvalumab plus chemotherapy, followed by olaparib and durvalumab for pMMR endometrial cancer, and single-agent durvalumab for dMMR disease.

Durvalumab plus chemotherapy sustained an overall survival benefit vs chemotherapy alone in locally advanced or metastatic biliary tract cancer.

Pembrolizumab plus bevacizumab and CAPOX produced responses in pMMR/MSS metastatic colorectal cancer with high immune infiltrate.

Concordance between TAP score and CPS at matched thresholds indicate their viability for assessing PD-L1 expression in advanced gastric cancers.

The EA2201 trial evaluated nivolumab, ipilimumab, and short-course radiation therapy in patients with locally advanced rectal cancer.

Botensilimab and balstilimab demonstrated pathological responses across subsets of patients with resectable colon cancer.

A study found stage 3 colon cancer patients with PIK3CA mutations taking celecoxib post-surgery had longer survival and disease-free intervals.

The FDA has approved a companion diagnostic for niraparib plus abiraterone acetate in BRCA-mutated metastatic castration-resistant prostate cancer.

María-Victoria Mateos, MD, PhD, discusses subgroup results for belantamab mafodotin plus bortezomib/dexamethasone in relapsed/refractory myeloma

In case you missed any, below is a recap of every OncLive On Air episode that aired in June 2024.

Aparna Parikh, MD, discusses key findings from the HERKULES-3 study and what the future of the BRAF-mutated mCRC treatment paradigm may look like.

Kevin Kalinsky, MD, MS, discusses the outcomes of the postMONARCH study in patients with HR+/HER2– breast cancer following disease progression.

Liver transplantation plus chemotherapy demonstrated no concerning safety signals or long-term deterioration in QOL in patients with definitively unresectable CRC liver metastasis.